Rhythm Pharmaceuticals, Inc. RYTM Non-cash interest expense
Non-cash interest expense at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept rytm:NonCashInterestExpense.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s non-cash interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s non-cash interest expense?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported non-cash interest expense of $4.58M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s non-cash interest expense changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s non-cash interest expense decreased by 15.4% year-over-year, from $5.41M to $4.58M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s non-cash interest expense?
- Over 2 years (2022 to 2025), Rhythm Pharmaceuticals, Inc.'s non-cash interest expense has grown at a 95.4% compound annual growth rate (CAGR), from $5.39M to $20.58M.
- What does non-cash interest expense mean?
- This captures interest-related expenses that do not involve an immediate cash outflow, such as the amortization of debt discounts or premiums. It is essential for reconciling net income to cash flow from operations by isolating non-cash financing costs.